How can Value Added Medicines help shape the future of European healthcare?
Join us during #VAMweek2026 for our upcoming webinar, “Value Added Medicines: Shaping Europe’s Healthcare Future”.
Political stakeholders, industry leaders and healthcare experts will come together to discuss the growing role of Value Added Medicines (VAMs) in improving patient outcomes and strengthening healthcare systems across Europe.
VAMs are therapeutic products developed from known chemical or biological molecules that address healthcare needs and deliver meaningful improvements for patients, healthcare professionals and payers.
What are the different types of Value Added Medicines?
Repurposing / repositioning: Discovery of new uses for existing molecules to treat different conditions or reach new patient populations.
Reformulation: Changes to how a medicine is delivered and absorbed, for example through new dosage forms or routes of administration, easier preparation of final medicines, or improved release profiles.
Combination: Pairing several known molecules, or combining known molecules with medical devices or digital tools.
Agenda
The webinar will explore key developments shaping the VAM landscape in Europe and beyond, including:
Key trends and forecasts in European and global VAM markets, presented by Aurelio Arias – Director, EMEA Thought Leadership at IQVIA.
Hungary’s shift towards incremental innovation represented by VAMs, with Zoltán Kaló – Director General, National Health Insurance Fund in Hungary.
Opportunities and challenges of bringing innovative VAM solutions to European markets, presented by Alan Knox – Managing Director at Colonis and Vice Chair of the VAM Sector Group at Medicines for Europe.
How stakeholder collaboration can improve access to Value Added Medicines across Europe, with Marta Andreykiv – Head of Global Market Access Country Strategy at Viatris and Chair of the VAM Sector Group at Medicines for Europe.
By joining forces and speaking with a unified sector voice, we can address barriers, share evidence and help shape the market for Value Added Medicines.
Together, we can raise awareness and support political interest in equitable and timely access for patients across Europe, incentivise innovation around off-patent molecules to optimise healthcare resources, bring better-designed products to market and foster European competitiveness.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
